loader image

Excellent animal proof of
concept studies with multiple
mechanism of actions (MOAs)

Scientific Background

FHL believes that neurodegenerative diseases are complex syndromes with multiple underlying causes, such as genetic as well as environmental factors with many symptoms unique for different patients. We see diseases and patients differently with our precision-medicine approach in a highly patient-focused model.

Our multiple assets of 8 drug candidates and combo drugs have demonstrated excellent animal proof of concept with many promising mechanism of action (MOA). FHL strives to identify cohorts of specific patients to which we can apply appropriate drug candidates based on particular MOAs with the aim of finding the right treatment drugs for right patient.

Mechanisms Under Development




IL-12 p40 inhibitor
PPAR-α agonist
RANTES and eotaxin inhibitor
TLR2- MyD88 inhibitor
NF-κB inhibitor
CCR5 inhibitor
Neuroprotection and anti-inflammation






Featured Publications

Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo

FHL-401 | Demonstrated that FHL-401’s TLR2-MyD88 mechanism can reduce glial inflammation and decrease α-syn spreading, two key markers of Parkinson’s disease, in a mouse animal model.

Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease via PPARα-Dependent Astrocytic GDNF Pathway

FHL-301 | Establishes that oral administration of FHL-301 protects dopaminergic neurons in an animal model of Parkinson’s disease via involvement of PPARα and GDNF.

IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rβ1 internalization and suppress EAE

FHL-701 | Showed that FHL-701’s IL-12 based mechanism can inhibit disease processes of autoimmmune disorders in a mouse animal model.

Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys

FHL-601 | Demonstrates that FHL-601’s CCR5 mechanism can improve Parkinson’s disease markers, including protection of neurotransmitters and motor function, in a monkey animal model.

Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson’s Disease Via Astrocytic GDNF

FHL-101 | Shows that the metabolite of FHL-101 increases GDNF level, which is known to promote dopaminergic neuronal survival in cellular and animal models of Parkinson’s Disease , in mice models.